Figure 1From: Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study Gefinitib vs. erlotinib. Kaplan-Meier analyses of time to progression (a) and survival since initiating TKI therapy (b) in months among gefitinib users (solid line) and erlotinib users (dashed line).Back to article page